Table 4 Relapses
From: Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab | 1st relapse | |
|---|---|---|
N (%) | joint p value* | |
< 0.001 | ||
During treatment | 18/186 (9.7%) | |
Before treatment | 25/186 (13.4%) | |
After treatment | 24/67 (35.8%) |
From: Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab | 1st relapse | |
|---|---|---|
N (%) | joint p value* | |
< 0.001 | ||
During treatment | 18/186 (9.7%) | |
Before treatment | 25/186 (13.4%) | |
After treatment | 24/67 (35.8%) |